Contribution of virion ICAM-1 to human immunodeficiency virus infectivity and sensitivity to neutralization.
Incorporation of the intercellular adhesion molecule ICAM-1 into human immunodeficiency virus type 1 (HIV-1) particles increased virus infectivity on peripheral blood mononuclear cells (PBMCs) by two- to sevenfold. The degree of ICAM-1-mediated enhancement was greater for viruses bearing envelope glycoproteins derived from primary HIV-1 isolates than for those bearing envelope glycoproteins from laboratory-adapted strains. Treatment of target PBMCs with an antibody against LFA-1, a principal ICAM-1 receptor, was able to nullify the ICAM-1-mediated enhancement. The incorporation of ICAM-1 rendered HIV-1 virions less susceptible to neutralization by a monoclonal antibody directed against the viral envelope glycoproteins. Surprisingly, an antibody against ICAM-1 completely neutralized infection by ICAM-1-containing viruses, reducing the efficiency of virus entry by almost 100-fold. Thus, HIV-1 neutralization by an ICAM-1-directed antibody involves more than an inhibition of the contribution of ICAM-1 to virus entry.
Rizzuto
C D
CD
Division of Human Retrovirology, Dana-Farber Cancer Institute, Boston, Massachusetts 01225, USA.
Sodroski
J G
JG
D000818:Animals; D019556:COS Cells; D002478:Cells, Cultured; D015752:Genes, env; D015754:Genes, nef; D015497:HIV-1 / Q000472:pathogenicity*; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000276:immunology / Q000378:metabolism*; D007963:Leukocytes, Mononuclear / Q000382:microbiology; D009500:Neutralization Tests; D011533:Proviruses / Q000737:chemistry; D015728:Receptors, HIV / Q000737:chemistry / Q000378:metabolism; D014162:Transfection; D014759:Viral Envelope Proteins / Q000502:physiology*; D014771:Virion / Q000737:chemistry / Q000276:immunology / Q000378:metabolism*
D015728:Receptors, HIV; D014759:Viral Envelope Proteins; D018799:Intercellular Adhesion Molecule-1